中疾控启动集中采购，二价HPV疫苗免费接种越来越近了

Core Viewpoint - The inclusion of the HPV vaccine in China's national immunization program signifies a significant step towards improving women's health, with a budget of approximately 425 million yuan for the procurement of 15.4465 million doses of the bivalent HPV vaccine, priced at no more than 27.5 yuan per dose [3][4][6]. Group 1: Procurement Details - The procurement unit for the HPV vaccine is the Chinese Center for Disease Control and Prevention [4]. - The total budget for the 2025 national immunization program for the bivalent HPV vaccine is 424.78 million yuan [5]. - The procurement will involve 15.4465 million doses, with each dose being a 0.5 mL liquid injection containing specific HPV proteins [5]. Group 2: Health Context - Cervical cancer is the fourth most common malignant tumor among women globally, with rising incidence and mortality rates in China, particularly among younger populations [6]. - Evidence indicates that HPV vaccination is effective in preventing cervical cancer, especially when administered to younger age groups [6]. - As of the end of 2024, 143 out of 194 member countries of the World Health Organization have included the HPV vaccine in their national immunization programs, representing 74% of the countries [6]. Group 3: Market Dynamics - Several regions in China have already initiated free HPV vaccination programs for eligible girls [6]. - The timing for including the HPV vaccine in the national immunization program is deemed mature due to sufficient supply, accumulated efficacy data, and decreasing prices [6]. - The procurement specifies that only two manufacturers will be involved, which implies that one of the currently available bivalent HPV vaccines will not be awarded a contract [7].